8 results
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
Lung Cancer - Progression-free ... #EBM #Honc #PACIFIC ... Durvalumab #NSCLC #NEJM
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free ... Survival #EBM ... #Honc #Osimertinib ... NSCLC #Survival #NEJM
IgM and Non-IgM - Risk and Type of Progression #EBM #Honc #MGUS #Progression #IgM #NonIgM #MultipleMyeloma
Risk and Type of Progression ... #EBM #Honc #MGUS ... #Progression #IgM ... MultipleMyeloma #NEJM
Cumulative Incidence of Progression of MGUS, with Death Accounted for as a Competing Risk #EBM #Honc
Cumulative Incidence of Progression ... Competing Risk #EBM ... #Honc #MGUS #Progression ... #IgG #MGUS #NEJM
Pulmonary Renal Syndromes - OnePager Summary
Autoimmune ANCA vasculitis (AAV): GPA (granulomatous with polyangiitis), EGPA (eosinophilic granulomatosis
antibody, Anti-GBM ... ESR and CRP (non-specific ... usually low in anti-GBM ... blood retum in serial ... Path: rapidly progressive
CNS Infection in HIV / AIDS - Differential Diagnosis Framework

Principles of HIV-Associated CNS Opportunistic Infections:
 •
headache, altered mental ... PCR nearly 100% specific ... effect/Edema • EBV ... abnormalities, rapidly progressive ... sensitive and specific
Vasculitis and Vasculitides - Differential Diagnosis Framework

When to Consider Vasculitis:
 • Purpura, ischemic skin lesions
 •
proteinuria, rapidly progressing ... Associated - ANCA specific ... glomerulonephritis) • Anti-GBM ... + MPO-ANCA MEDIUM ... aortic aneurysm • Medium
Vasculitis - Differential Diagnosis Framework

When to Consider Vasculitis:
• Purpura, ischemic skin lesions
• Mononeuritis multiplex
• Hematuria, proteinuria,
proteinuria, Rapidly progressing ... primary condition MEDIUM ... is 50 years • Progressive ... Pauci Immune (ANCA specific ... pain and GN Anti-GBM